The start-ups Oxolife, Peptomyc and aptaTargets, with which GENESIS Biomed collaborates, are advancing in their maturity with the initiation and development of clinical phases and are approaching a...
H.I.G. Capital, LLC, a leading global alternative investment firm with $45 billion of equity capital under management, is pleased to announce that one of its affiliates has acquired Aspire Pharma Limi...
Mediktor has announced that it has raised a €11 million financing round to keep on improving their elaborate technology and expand their international presence. The round was led by European healtht...
Columbus Venture Partners ha anunciado la creación de Syngoi Technologies, una empresa biotecnológica dedicada a la producción de ADN sintético a través de un nuevo proceso enzimático, propiedad...
Laminar Pharmaceuticals, compañía biotech dedicada principalmente al desarrollo de terapias antitumorales y neurológicas, abre una nueva ronda de financiación con Fellow Funders con el objetivo de...
Capital Cell, compañía de inversión especializada en biotecnología y salud, ha cerrado el último trimestre del 2021 con 14.044.000 MEUR levantados para empresas del sector biomédico como Nexkin ...
MOA Foodtech ha captado 1,5 millones de euros en una ronda, liderada por Clave Capital, a través de la que podrá escalar su producción de proteínas sostenibles para alimentación y ganar presencia...
Agomab has announced that it has entered into a definitive agreement under which it will acquire Origo Biopharma S.L., a Spanish clinical-stage biotechnology company developing organ-restricted small ...
Ysios Capital, a leading Spanish biotechnology venture capital firm, has announced that its portfolio company Aura Biosciences Inc. has priced its initial public offering (IPO) and is trading on the N...
Así lo indican los datos del reciente estudio internacional “Seeds of change. Measuring the return from pharmaceutical innovation 2020”realizado por Deloitte, el cual analiza anualmente el rendim...
Con esta operación, Magnum completa la tercera operación de su fondo Magnum Capital III, después de las inversiones en los grupos educativos DIGITALENT y METRODORA. Magnum ha contado con el asesora...
Under the terms of the acquisition agreement, Vifor Pharma will acquire 100% of the outstanding shares in Sanifit Therapeutics, receiving full global rights for SNF472, further enhancing the company